It was a down day for Acurx Pharmaceuticals (ACXP) on Friday, with shares dropping sharply after the company delivered its latest financial update. The clinical-stage biopharmaceutical firm reported a net loss for the fourth quarter of 2025, which seems to have spooked some investors. But if you look a little closer, the numbers aren't all bad news.
The company posted a net loss of 73 cents per diluted share. That's a loss, sure, but here's the thing: Wall Street analysts were expecting it to be much worse. The consensus estimate was for a loss of $1.65 per share. So, in the quirky world of biotech investing, losing less money than you were supposed to can sometimes be seen as a win. The market, however, wasn't in a forgiving mood on Friday.
Perhaps more importantly for a company still in the development phase, Acurx's cash situation looks healthier. It ended the quarter with $7.6 million in cash, which is a notable jump from the $3.7 million it had at the same time last year. During the fourth quarter, the company also tapped its Equity Line of Credit to bring in approximately $1.5 million in fresh capital. For a pre-revenue biotech, that runway is everything.
So what is Acurx spending that money on? The company is in the business of trying to invent new antibiotics, which is a notoriously tough but critically important area of medicine. Its lead candidate is a drug called Ibezapolstat, which is gearing up for international Phase 3 clinical trials. The target is Clostridioides difficile infection, or C. diff, a nasty and sometimes deadly gastrointestinal bug.
Acurx's broader mission is to develop a new class of antibiotics specifically for infections caused by bacteria that global health authorities like the WHO and the CDC have labeled as "priority pathogens." These are the superbugs—the ones that are becoming resistant to existing treatments. The company's strategy is to focus on antibiotics with a "Gram-positive selective spectrum," aiming its firepower at particularly difficult-to-treat bacterial infections. In a world where antibiotic resistance is a growing crisis, successful new therapies are desperately needed.
Looking ahead, the company is scheduled to provide its next financial update on May 12, 2026. Analysts are already starting to model that out, with the current consensus estimate for earnings per share sitting at a loss of $1.24. That's an improvement from the previous estimate of a $2.20 loss, suggesting some optimism is creeping in about the company's financial trajectory.
Despite the seemingly mixed-but-leaning-positive report, investors headed for the exits on Friday. According to market data, Acurx Pharmaceuticals shares were down 19.16%, trading at $4.24 at the time of publication.
